This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Severe. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
When pimozide is taken with fluvoxamine or nefazodone, your body may process pimozide more slowly. When pimozide is taken with citalopram, escitalopram, or sertraline, the effects of pimozide on your heart may be greater.
What might happen:
You may develop an irregular heartbeat, which may be life threatening.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know right away that you are taking these medicines together and all other medicines you are taking. Let your doctor know right away if you notice and irregular heartbeat or have any dizziness or fainting episodes.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Luvox (fluvoxamine maleate) US prescribing information. Jazz Pharmaceuticals, Inc. January, 2017.
2.Serzone (nefazodone hydrochloride) US prescribing information. Bristol-Myers Squibb Company January, 2005.
3.Orap (pimozide) US prescribing information. Gate Pharmaceuticals August, 2011.
4.Celexa (citalopram hydrobromide) US prescribing information. Forest Laboratories Inc. January, 2017.
5.Lexapro (escitalopram oxalate) US prescribing information. Forest Pharmaceuticals Inc. January, 2017.
6.Zoloft (sertraline) US prescribing information. Pfizer Inc. December, 2016.
7.Desta Z, Kerbusch T, Soukhova N, Richard E, Ko JW, Flockhart DA. Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther 1998 May;285(2):428-37.
8.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
9.Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, Middleton B, Bates DW. High-priority drug-drug interactions for use in electronic health records. J Am Med Inform Assoc 2012 Sep-Oct; 19(5):735-43.